Transarterial Chemoembolisation for Advanced Hepatocellular Carcinoma: Results from a North American Cancer Centre

The survival probabilities at 1 and 2 years after TACE were comparable with results in randomised studies from Europe and Asia. Most patients tolerated TACE well, but clinicians need to be aware that moderately severe side-effects require close monitoring and prompt intervention.